BeiGene, Ltd. (ONC)
NASDAQ · Healthcare · Biotechnology
BeiGene, Ltd. is a Healthcare company with a market capitalization of $29.04B and a trailing P/E ratio of 63.3.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $1.96 | $0.81 | +142.0% |
| Q4 2025 | February 26, 2026 | $0.58 | $1.53 | -62.1% |
| Q3 2025 | November 6, 2025 | $1.09 | $0.86 | +26.7% |
| Q2 2025 | August 6, 2025 | $0.84 | $0.26 | +223.1% |
| Q1 2025 | May 7, 2025 | $0.01 | $-0.74 | +101.4% |
| Q4 2024 | February 27, 2025 | $-1.43 | $-1.01 | -41.6% |
Other Biotechnology Stocks
Frequently Asked Questions
What is BeiGene, Ltd.'s market cap?
As of June 29, 2026, BeiGene, Ltd. (ONC) has a market capitalization of $29.04B.
What is BeiGene, Ltd.'s P/E ratio?
BeiGene, Ltd. trades at a trailing price-to-earnings (P/E) ratio of 63.3. Its forward P/E is 45.5.
Does BeiGene, Ltd. pay a dividend?
BeiGene, Ltd. does not currently pay a dividend.
What sector is ONC in?
BeiGene, Ltd. is in the Healthcare sector, specifically the Biotechnology industry.
What was BeiGene, Ltd.'s revenue?
In its latest reported fiscal year (ending December 31, 2025), BeiGene, Ltd. reported revenue of $5.34B and net income of $286.93M.
Ask your own questions about ONC
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.